#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15016	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2073	718.3	0	.	n	.	0	A69G	SNP	69	69	A	300	300	G	839	G,A	605,186	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15016	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2073	718.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1681	1681	T	830	T	768	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15016	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2073	718.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1415	1415	C	856	C	791	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15016	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2073	718.3	0	HET	.	.	.	C393T	.	393	393	C	624	624	C	814	C,T	380,382	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28556	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3509	811.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1656	1656	A	972	A	910	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28556	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3509	811.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2290	2290	C	905	C,T	819,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28556	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3509	811.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2364	2364	A	873	A,G	823,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28556	23S	2890	2890	99.93	23S.l6.c17.ctg.1	3509	811.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2916	2916	C	870	C	813	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2062	folP	852	852	99.88	folP.l15.c4.ctg.1	1373	148.8	0	.	p	.	0	E151K	NONSYN	451	453	GAA	711	713	AAA	222;226;223	A,G;A;A	197,1;202;201	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2062	folP	852	852	99.88	folP.l15.c4.ctg.1	1373	148.8	1	SNP	p	R228S	1	.	.	682	684	AGC	942	944	AGC	199;199;200	A;G;C	187;184;184	folP.WHO_M_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6050	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3370	178.8	1	SNP	p	S91F	0	.	.	271	273	TCC	567	569	TCC	187;188;187	T;C;C	173;174;175	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6050	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3370	178.8	1	SNP	p	D95N	0	.	.	283	285	GAC	579	581	GAC	189;190;187	G;A;C	177;175;176	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6050	gyrA	2751	2751	100.0	gyrA.l6.c30.ctg.1	3370	178.8	1	SNP	p	D95G	0	.	.	283	285	GAC	579	581	GAC	189;190;187	G;A;C	177;175;176	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1772	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1259	139.8	1	SNP	p	G45D	0	.	.	133	135	GGC	459	461	GGC	231;230;232	G;G;C	214;211;214	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	828	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c17.ctg.1	986	83.6	0	.	n	.	0	A197.	DEL	197	197	A	589	589	A	178	A	169	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	828	mtrR_promoter	250	250	99.2	mtrR_promoter.l15.c17.ctg.1	986	83.6	0	.	n	.	0	.201T	INS	201	201	C	594	594	T	181	T	171	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5146	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2887	177.3	1	SNP	p	D86N	0	.	.	256	258	GAC	536	538	GAC	187;186;187	G,A;A;C	178,1;176;178	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5146	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2887	177.3	1	SNP	p	S87I	0	.	.	259	261	AGT	539	541	AGT	190;191;193	A,C;G;T	178,1;181;183	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5146	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2887	177.3	1	SNP	p	S87R	0	.	.	259	261	AGT	539	541	AGT	190;191;193	A,C;G;T	178,1;181;183	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5146	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2887	177.3	1	SNP	p	S87W	0	.	.	259	261	AGT	539	541	AGT	190;191;193	A,C;G;T	178,1;181;183	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5146	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2887	177.3	1	SNP	p	S88P	0	.	.	262	264	TCC	542	544	TCC	193;190;187	T;C;C	183;184;180	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4434	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2864	154.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1713	1715	GGC	229;223;222	G;G;C	217;210;206	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2515	170.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1322	1324	GCA	221;220;221	G;C;A	202;198;204	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2515	170.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1325	1327	ATC	224;225;224	A;T;C	208;208;206	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2515	170.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1337	1339	GTG	225;222;223	G;T;G	215;211;210	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2515	170.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1337	1339	GTG	225;222;223	G;T;G	215;211;210	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2515	170.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1841	1843	ACC	232;232;233	A,G;C;C	206,1;214;217	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2515	170.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1895	1897	GCG	210;210;210	G;C;G	187;168;177	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2515	170.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1895	1897	GCG	210;210;210	G;C;G	187;168;177	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2515	170.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2018	2020	GGC	200;198;198	G;G,A;C	181;180,1;181	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2515	170.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2027	2029	GGC	192;192;190	G;G,C;C,G	173;172,1;169,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4294	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2515	170.3	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2045	2047	CTG	182;184;187	C,G;T,G;G	144,4;136,1;148	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5926	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3179	185.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1674	1676	CCG	215;213;211	C;C;G	194;198;196	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2606	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1893	137.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	582	582	C	183	C	165	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	T87A	NONSYN	259	261	ACT	478	480	GCT	241;246;248	G;C;T	218;224;230	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	T89S	NONSYN	265	267	ACC	484	486	AGC	251;252;251	A,G;G;C	233,1;239;229	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	K120D	NONSYN	358	360	AAG	577	579	GAC	232;227;224	G;A;C	207;207;211	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	E137K	NONSYN	409	411	GAA	628	630	AAA	243;242;241	A;A;A	227;223;223	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	646	648	CAA	239;241;240	C;A;A,C	221;225;220,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	V151A	NONSYN	451	453	GTA	670	672	GCA	252;254;257	G,A;C;A	233,1;233;233	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	T213A	NONSYN	637	639	ACA	856	858	GCA	212;213;214	G;C;A,T	198;198;200,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	I216T	NONSYN	646	648	ATC	865	867	ACC	215;213;209	A;C;C	198;203;199	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	976	978	CAA	208;207;208	C;A;A	198;198;197	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	.	INDELS	760	761	AC	980	983	ATCG	203;202;201;201	A;T,C;C;G	193;188,1;191;189	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	.	INDELS	763	764	TG	987	989	AGT	206;204;203	A;G;T	193;190;189	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	A257D	NONSYN	769	771	GCT	994	996	GAT	216;215;214	G;A,G;T	198;198,1;198	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1102	1104	AGT	228;225;226	A;G;T,C	213;212;201,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1108	1110	GAC	226;227;224	G;A;C	208;211;204	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2852	porB1b	1041	1041	97.33	porB1b.l15.c17.ctg.1	1402	201.3	0	.	p	.	0	E326K	NONSYN	976	978	GAA	1201	1203	AAA	268;270;273	A;A;A	246;250;252	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10998	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4853	225.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1983	1985	CAT	256;254;256	C;A;T	235;235;236	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1310	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1189	109.9	1	SNP	p	V57M	1	.	.	169	171	ATG	584	586	ATG	267;264;264	A;T;G,A	246;245;243,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
